NEW YORK (GenomeWeb) – Interpace Diagnostics said today that Premera Blue Cross, a regional health plan, has agreed to cover its ThyraMIR test for more than 2 million members located primarily in Washington, Oregon, and Alaska.

Premera Blue Cross has a network of more than 38,000 physicians, hospitals, laboratories, and other healthcare providers across the Northwest, Interpace said.

Its ThyraMIR assay is covered for thyroid nodules deemed indeterminate by standard cytopathological analysis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.